Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Proteomics - Clinical Applications

Volumn 10, Issue 4, 2016, Pages 470-484

  Del Boccio, Piero ^a   Rossi, Claudia ^a   di Ioia, Maria ^a   Cicalini, Ilaria ^a   Sacchetta, Paolo ^a   Pieragostino, Damiana ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biomarkers; Metabolomics; Multiple sclerosis; Personalized medicine; Proteomics

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL PROTEIN; CHITINASE 3 LIKE PROTEIN 1; CHOLINE; CXCL13 CHEMOKINE; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; HAPTAGLOBIN PROTEIN; INOSITOL; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; JAGGED1; LACTIC ACID; MANNOSE; MICRORNA; MYELIN BASIC PROTEIN; NITRIC OXIDE; OSTEOPONTIN; OXALOACETIC ACID; PHENYLALANINE; PHOSPHATIDYLETHANOLAMINE; PREALBUMIN; PROTEOME; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; INTERLEUKIN DERIVATIVE; MATRIX METALLOPROTEINASE; MYELIN PROTEIN;

CEREBROSPINAL FLUID; CLINICAL EVALUATION; DOWN REGULATION; GENOME; HUMAN; LUMBAR PUNCTURE; METABOLOMICS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROFILING; PROTEOMICS; REVIEW; RISK BENEFIT ANALYSIS; UPREGULATION; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METABOLOME; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PROCEDURES;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTERLEUKINS; MATRIX METALLOPROTEINASES; METABOLOME; METABOLOMICS; MICE; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; MYELIN PROTEINS; PRECISION MEDICINE; PROTEIN INTERACTION MAPPING; PROTEOMICS;

EID: 84960449036     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500083     Document Type: Review

References (119)

1. Cornetta, K., Brown, C. G., Balancing personalized medicine and personalized care. Acad. Med. 2013, 88, 309-313.
2. Gotovac, K., Hajnsek, S., Pasic, M. B., Pivac, N., Borovecki, F., Personalized medicine in neurodegenerative diseases: how far away? Mol. Diagn. Ther. 2014, 18, 17-24.
3. Jimenez, N., Galinkin, J. L., Personalizing pediatric pain medicine: using population-specific pharmacogenetics, genomics, and other -omics approaches to predict response. Anesth. Anal. 2015, 121, 183-187.
4. Lugaresi, A., di Ioia, M., Travaglini, D., Pietrolongo, E. et al., Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr. Dis. Treat. 2013, 9, 893-914.
5. Kim, W., Zandona, M. E., Kim, S. H., Kim, H. J., Oral disease-modifying therapies for multiple sclerosis. J. Clin. Neurol. 2015, 11, 9-19.
6. Gallo, P., Van Wijmeersch, B., Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur. J. Neurol. 2015, 22 Suppl 2, 14-21.
7. Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M. et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69, 292-302.
8. Giovannoni, G., Cerebrospinal fluid analysis. Handb. Clin. Neurol. 2014, 122, 681-702.
9. Fernandez, O., Integrating the tools for an individualized prognosis in multiple sclerosis. J. Neurol. Sci. 2013, 331, 10-13.
10. Villar, L., Garcia-Barragan, N., Espino, M., Roldan, E. et al., Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult. Scler. 2008, 14, 183-187.
11. Semra, Y. K., Seidi, O. A., Sharief, M. K., Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 2002, 122, 132-139.
12. Haghighi, S., Andersen, O., Oden, A., Rosengren, L., Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol. Scand. 2004, 109, 97-99.
13. Berger, T., Rubner, P., Schautzer, F., Egg, R. et al., Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349, 139-145.
14. Canto, E., Reverter, F., Morcillo-Suarez, C., Matesanz, F. et al., Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult. Scler. 2012, 18, 983-990.
15. Comabella, M., Fernandez, M., Martin, R., Rivera-Vallve, S. et al., Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133, 1082-1093.
16. Canto, E., Tintore, M., Villar, L. M., Costa, C. et al., Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015, 138, 918-931.
17. Fragoso, Y. D., Boggild, M., Macias-Islas, M. A., Carra, A. et al., The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin. Neurol. Neurosurg. 2013, 115, 154-159.
18. Marta, M., Giovannoni, G., Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol. Disord. Drug Targets 2012, 11, 610-623.
19. Wattjes, M. P., Rovira, A., Miller, D., Yousry, T. A. et al., Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat. Rev. 2015, 11, 597-606.
20. Creeke, P. I., Farrell, R. A., Clinical testing for neutralizing antibodies to interferon-beta in multiple sclerosis. Ther. Adv. Neurol. Disord. 2013, 6, 3-17.
21. Bertolotto, A., Evaluation of the impact of neutralizing antibodies on IFNbeta response. Clin. Chim. Acta 2015, 449, 31-36.
22. Matas, E., Bau, L., Martinez-Iniesta, M., Romero-Pinel, L. et al., Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PloS One 2014, 9, e112758.
23. Bertolotto, A., Capobianco, M., Amato, M. P., Capello, E. et al., Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol. Sci. 2014, 35, 307-316.
24. Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L. et al., The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007, 69, 1391-1403.
25. Vennegoor, A., Rispens, T., Strijbis, E. M., Seewann, A. et al., Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult. Scler 2013, 19, 593-600.
26. Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S. et al., Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 2014, 76, 802-812.
27. Villar, L. M., Costa-Frossard, L., Masterman, T., Fernandez, O. et al., Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann. Neurol. 2015, 77, 447-457.
28. Calais, G., Forzy, G., Crinquette, C., Mackowiak, A. et al., Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult. Scler. 2010, 16, 87-92.
29. Lebrun, C., Forzy, G., Collongues, N., Cohen, M. et al., Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. Rev. Neurol. 2015, 171, 390-393.
30. Lolli, F., Franciotta, D., Oligoclonal bands in tears. Mult. Scler. 2010, 16, 760; author reply 761.
31. Pieragostino, D., D'Alessandro, M., di Ioia, M., Di Ilio, C. et al., Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases. Proteomics Clin. Appl. 2015, 9, 169-186.
32. Salvisberg, C., Tajouri, N., Hainard, A., Burkhard, P. R. et al., Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin. Appl. 2014, 8, 185-194.
33. Farias, A. S., Santos, L. M., How can proteomics elucidate the complexity of multiple sclerosis? Proteomics Clin. Appl. 2015, 9, 844-847.
34. Goldsmith, P., Fenton, H., Morris-Stiff, G., Ahmad, N. et al., Metabonomics: a useful tool for the future surgeon. J. Surg. Res. 2010, 160, 122-132.
35. Villas-Boas, S. G., Mas, S., Akesson, M., Smedsgaard, J., Nielsen, J., Mass spectrometry in metabolome analysis. Mass Spectrom. Rev. 2005, 24, 613-646.
36. Fuzery, A. K., Levin, J., Chan, M. M., Chan, D. W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10, 13.
37. Mischak, H., Kolch, W., Aivaliotis, M., Bouyssie, D. et al., Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin. Appl 2010, 4, 464-478.
38. Fiehn, O., Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48, 155-171.
39. Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., Griffin, J. L., Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 2011, 40, 387-426.
40. van der Greef, J., Stroobant, P., van der Heijden, R., The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol. 2004, 8, 559-565.
41. Rhee, S. Y., Wood, V., Dolinski, K., Draghici, S., Use and misuse of the gene ontology annotations. Nat. Rev. Genet. 2008, 9, 509-515.
42. Sirolli, V., Rossi, C., Di Castelnuovo, A., Felaco, P. et al., Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint. Blood Transfus. 2012, 10 Suppl 2, s78-s88.
43. Rizza, S., Copetti, M., Rossi, C., Cianfarani, M. A. et al., Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis 2014, 232, 260-264.
44. Stohr, R., Cavalera, M., Menini, S., Mavilio, M. et al., Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. Atherosclerosis 2014, 235, 438-443.
45. Di Liberato, L., Arduini, A., Rossi, C., Di Castelnuovo, A. et al., L-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis. J. Nephrol. 2014, 27, 699-706.
46. D'Aguanno, S., Barcaroli, D., Rossi, C., Zucchelli, M. et al., p63 isoforms regulate metabolism of cancer stem cells. J. Proteome Res. 2014, 13, 2120-2136.
47. Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S. et al., Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis. 2014, 5, e1336.
48. Pieragostino, D., D'Alessandro, M., di Ioia, M., Rossi, C. et al., An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol. Biosys. 2015, 11, 1563-1572.
49. Reinke, S. N., Broadhurst, D. L., Sykes, B. D., Baker, G. B. et al., Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Mult Scler. 2014, 20, 1396-1400.
50. Jones, H. H., Jones, H. H., Jr., Bunch, L. D., Biochemical studies in multiple sclerosis. Ann. Intern. Med. 1950, 33, 831-840.
51. Mathur, D., Lopez-Rodas, G., Casanova, B., Marti, M. B., Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis. Front. Neurol. 2014, 5, 250.
52. Zhao, C., Du, H., Xu, L., Wang, J. et al., Metabolomic analysis revealed glycylglycine accumulation in astrocytes after methionine enkephalin administration exhibiting neuron protective effects. J. Pharm . Biomed. Anal. 2015, 115, 48-54.
53. Galea, I., Palin, K., Newman, T. A., Van Rooijen, N. et al., Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia 2005, 49, 375-384.
54. Skripuletz, T., Manzel, A., Gropengiesser, K., Schafer, N. et al., Pivotal role of choline metabolites in remyelination. Brain 2015, 138, 398-413.
55. Del Boccio, P., Pieragostino, D., Di Ioia, M., Petrucci, F. et al., Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J. Proteomics 2011, 74, 2826-2836.
56. Hassan-Smith, G., Wallace, G. R., Douglas, M. R., Sinclair, A. J., The role of metabolomics in neurological disease. J. Neuroimmunol. 2012, 248, 48-52.
57. Lutz, N. W., Viola, A., Malikova, I., Confort-Gouny, S. et al., Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PloS One 2007, 2, e595.
58. Noga, M. J., Dane, A., Shi, S., Attali, A. et al., Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 2012, 8, 253-263.
59. Wheeler, D., Bandaru, V. V., Calabresi, P. A., Nath, A., Haughey, N. J., A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008, 131, 3092-3102.
60. Giovannoni, G., Silver, N. C., O'Riordan, J., Miller, R. F. et al., Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult. Scler. 1999, 5, 335-341.
61. Brundin, L., Morcos, E., Olsson, T., Wiklund, N. P., Andersson, M., Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J. Neurol. 1999, 6, 585-590.
62. Acar, G., Idiman, F., Idiman, E., Kirkali, G. et al., Nitric oxide as an activity marker in multiple sclerosis. J. Neurol. 2003, 250, 588-592.
63. Rejdak, K., Eikelenboom, M. J., Petzold, A., Thompson, E. J. et al., CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004, 63, 1439-1445.
64. Regenold, W. T., Phatak, P., Makley, M. J., Stone, R. D., Kling, M. A., Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J. Neurol. Sci. 2008, 275, 106-112.
65. Nicoli, F., Vion-Dury, J., Confort-Gouny, S., Maillet, S. et al., Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C. R. Acad. Sci III 1996, 319, 623-631.
66. Sinclair, A. J., Viant, M. R., Ball, A. K., Burdon, M. A. et al., NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-a diagnostic tool? NMR Biomed. 2010, 23, 123-132.
67. Comabella, M., Montalban, X., Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014, 13, 113-126.
68. Waubant, E., Goodkin, D., Bostrom, A., Bacchetti, P. et al., IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003, 60, 52-57.
69. Fainardi, E., Castellazzi, M., Bellini, T., Manfrinato, M. C. et al., Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult. Scler. 2006, 12, 294-301.
70. Benesova, Y., Vasku, A., Novotna, H., Litzman, J. et al., Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 2009, 15, 316-322.
71. Avolio, C., Ruggieri, M., Giuliani, F., Liuzzi, G. M. et al., Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 2003, 136, 46-53.
72. Aung, L. L., Mouradian, M. M., Dhib-Jalbut, S., Balashov, K. E., MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. J. Neuroimmunol. 2015, 278, 185-189.
73. Bornsen, L., Khademi, M., Olsson, T., Sorensen, P. S., Sellebjerg, F., Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult. Scler. 2011, 17, 32-42.
74. Comabella, M., Pericot, I., Goertsches, R., Nos, C. et al., Plasma osteopontin levels in multiple sclerosis. J. Neuroimmunol. 2005, 158, 231-239.
75. Kivisakk, P., Healy, B. C., Francois, K., Gandhi, R. et al., Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult. Scler. 2014, 20, 438-444.
76. Vogt, M. H., Floris, S., Killestein, J., Knol, D. L. et al., Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J. Neuroimmunol. 2004, 155, 155-160.
77. Stoop, M. P., Singh, V., Stingl, C., Martin, R. et al., Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J. Proteome Res. 2013, 12, 1101-1107.
78. Singh, V., Stingl, C., Stoop, M. P., Zeneyedpour, L. et al., Proteomics urine analysis of pregnant women suffering from multiple sclerosis. J. Proteome Res. 2015, 14, 2065-2073.
79. Chang, K. H., Tseng, M. Y., Ro, L. S., Lyu, R. K. et al., Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. Clin. Chim. Acta 2013, 417, 26-30.
80. Jiang, S. F., Lu, Q. Y., Hu, S., Chen, Y. et al., Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients. Genetics Mol. Res. 2014, 13, 9292-9299.
81. Harris, V. K., Sadiq, S. A., Biomarkers of therapeutic response in multiple sclerosis: current status. Mol. Diagn. Ther. 2014, 18, 605-617.
82. Ragheb, S., Li, Y., Simon, K., VanHaerents, S. et al., Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult. Scler. 2011, 17, 819-829.
83. Alvarez, E., Piccio, L., Mikesell, R. J., Klawiter, E. C. et al., CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult. Scler. 2013, 19, 1204-1208.
84. Sellebjerg, F., Bornsen, L., Khademi, M., Krakauer, M. et al., Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73, 2003-2010.
85. Khademi, M., Kockum, I., Andersson, M. L., Iacobaeus, E. et al., Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler. 2011, 17, 335-343.
86. Axelsson, M., Mattsson, N., Malmestrom, C., Zetterberg, H., Lycke, J., The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of neuroimmunology 2013, 264, 100-105.
87. Cross, A. H., Klein, R. S., Piccio, L., Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2012, 5, 311-319.
88. Piccio, L., Naismith, R. T., Trinkaus, K., Klein, R. S. et al., Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67, 707-714.
89. Martinez, M. A., Olsson, B., Bau, L., Matas, E. et al., Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult. Scler. 2015, 21, 550-561.
90. Malmestrom, C., Haghighi, S., Rosengren, L., Andersen, O., Lycke, J., Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61, 1720-1725.
91. Housley, W. J., Pitt, D., Hafler, D. A., Biomarkers in multiple sclerosis. Clin. Immunol. 2015, 161, 51-58.
92. Petzold, A., Eikelenboom, M. J., Gveric, D., Keir, G. et al., Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002, 125, 1462-1473.
93. Sarchielli, P., Greco, L., Stipa, A., Floridi, A., Gallai, V., Brain-derived neurotrophic factor in patients with multiple sclerosis. J. Neuroimmunol. 2002, 132, 180-188.
94. Frota, E. R., Rodrigues, D. H., Donadi, E. A., Brum, D. G. et al., Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci. Lett. 2009, 460, 130-132.
95. Damasceno, A., Damasceno, B. P., Cendes, F., Damasceno, A. et al., Serum BDNF levels are not reliable correlates of neurodegeneration in MS patients. Mult. Scler. Relat. Disord. 2015, 4, 65-66.
96. Kochanowski, J., Uchman, D., Litwiniuk, A., Kalisz, M. et al., Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatment-naive humans with multiple sclerosis. Neuroendocrinol. Lett. 2015, 36, 148-152.
97. Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J. et al., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172, 146-155.
98. Caminero, A., Comabella, M., Montalban, X., Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. Clin. Exp. Immunol. 2011, 166, 338-345.
99. Hinsinger, G., Galeotti, N., Nabholz, N., Urbach, S. et al., Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult. Scler. 2015, 21, 1251-1261.
100. Modvig, S., Degn, M., Roed, H., Sorensen, T. et al., Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult. Scler. 2015, 21, 1761-1770.
101. Modvig, S., Degn, M., Horwitz, H., Cramer, S. P. et al., Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PloS One 2013, 8, e77163.
102. Gaiano, N., Fishell, G., The role of notch in promoting glial and neural stem cell fates. Ann. Rev. Neurosci. 2002, 25, 471-490.
103. Stoop, M. P., Singh, V., Dekker, L. J., Titulaer, M. K. et al., Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PloS One 2010, 5, e12442.
104. Ottervald, J., Franzen, B., Nilsson, K., Andersson, L. I. et al., Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73, 1117-1132.
105. Perga, S., Giuliano Albo, A., Lis, K., Minari, N. et al., Vitamin D binding protein isoforms and apolipoprotein E in cerebrospinal fluid as prognostic biomarkers of multiple sclerosis. PloS One 2015, 10, e0129291.
106. Kroksveen, A. C., Opsahl, J. A., Guldbrandsen, A., Myhr, K. M. et al., Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et biophysica acta 2015, 1854, 746-756.
107. Amin, B., Maurer, A., Voelter, W., Melms, A., Kalbacher, H., New poteintial serum biomarkers in multiple sclerosis identified by proteomic strategies. Curr. Med. Chem. 2014, 21, 1544-1556.
108. Hybelova, M., Svatonova, J., Sobek, O., Adam, P. et al., Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS): comparison of particular subgroups of MS patients. Folia Microbiol. 2009, 54, 173-176.
109. Pieragostino, D., Del Boccio, P., Di Ioia, M., Pieroni, L. et al., Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. Proteomics 2013, 13, 1002-1009.
110. Del Boccio, P., Pieragostino, D., Lugaresi, A., Di Ioia, M. et al., Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 2007, 62, 201-204; discussion 205.
111. Pieragostino, D., Petrucci, F., Del Boccio, P., Mantini, D. et al., Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J. Proteomics 2010, 73, 579-592.
112. Stoop, M. P., Coulier, L., Rosenling, T., Shi, S. et al., Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol. Cell. Proteomics 2010, 9, 2063-2075.
113. Zhang, W., Li, F., Nie, L., Integrating multiple 'omics' analysis for microbial biology: application and methodologies. Microbiology 2010, 156, 287-301.
114. Mi, H., Guo, N., Kejariwal, A., Thomas, P. D., PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, 35, D247-D252.
115. Xia, J., Psychogios, N., Young, N., Wishart, D. S., MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009, 37, W652-W660.
116. Xia, J., Wishart, D. S., MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 2010, 26, 2342-2344.
117. Sedic, M., Gethings, L. A., Vissers, J. P., Shockcor, J. P. et al., Label-free mass spectrometric profiling of urinary proteins and metabolites from paediatric idiopathic nephrotic syndrome. Biochem. Biophys. Res. Commun. 2014, 452, 21-26.
118. Yizhak, K., Benyamini, T., Liebermeister, W., Ruppin, E., Shlomi, T., Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics 2010, 26, i255-i260.
119. Shlomi, T., Cabili, M. N., Ruppin, E., Predicting metabolic biomarkers of human inborn errors of metabolism. Mol. Syst. Biol. 2009, 5, 263.